Xeris Biopharma Holdings, Inc. (XERS) — Financial statements
Income statement, balance sheet, and cash flow for Xeris Biopharma Holdings, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 292↑43.7% | 203↑23.9% | 164↑48.7% | 110↑122.3% | 50 | |
| Cost of Revenue | 53↑45.0% | 37↑28.6% | 29↑26.6% | 23↑70.0% | 13 | |
| Gross Profit | 238↑43.4% | 166↑22.9% | 135↑54.4% | 88↑141.5% | 36 | |
| Operating Expenses | ||||||
| R&D Expenses | 31↑21.9% | 26↑14.4% | 22↑6.6% | 21↓16.7% | 25 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 182↑11.6% | 163↑11.9% | 146↑6.1% | 138↑9.6% | 126 | |
| Other Expenses | 0.00↓100.0% | 11↑0.0% | 11↑0.0% | 11↑1871.5% | 0.55 | |
| Operating Expenses | 214↑6.8% | 200↑11.5% | 179↑5.7% | 170↑12.0% | 151 | |
| Total Costs & Expenses | 267↑12.8% | 237↑13.8% | 208↑8.2% | 192↑16.7% | 165 | |
| Operating Results | ||||||
| Operating Income | 25↑174.0% | -34↑23.5% | -44↑46.3% | -82↑28.8% | -115 | |
| Depreciation & Amortization | 12↓3.7% | 13↓4.1% | 13↑3.9% | 13↑574.2% | 2 | |
| EBITDA | 13↑190.8% | -14↑41.0% | -24↑65.8% | -69↑39.0% | -114 | |
| EBIT | 0.55↑102.1% | -27↑27.9% | -37↑55.0% | -82↑29.0% | -116 | |
| Interest & Other Income | ||||||
| Net Interest Income | -24↑12.6% | -28↓27.4% | -22↓89.7% | -12↓67.8% | -7 | |
| Interest Income | 5↓10.9% | 5↑12.0% | 5↑84.3% | 3↑723.6% | 0.31 | |
| Interest Expense | 29↓12.3% | 33↑24.7% | 27↑88.7% | 14↑96.4% | 7 | |
| Non-Operating Income | 24↑446.4% | -7↑1.2% | -7↓17040.5% | 0.04↓89.2% | 0.39 | |
| Other Income / Expenses | -24↓3.8% | -23↓20.3% | -19↓37.8% | -14↓86.9% | -8 | |
| Income Before Tax | 0.55↑101.0% | -57↑10.1% | -64↑33.9% | -96↑21.7% | -123 | |
| Income Tax Expense | 0.00↑100.0% | -2↓81.6% | -1↑12.3% | -1 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 0.55↑101.0% | -55↑11.9% | -62↑34.2% | -95↑22.9% | -123 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 0.55↑101.0% | -55↑11.9% | -62↑34.2% | -95↑22.9% | -123 | |
| Bottom-Line Net Income | 0.55↑101.0% | -55↑11.9% | -62↑34.2% | -95↑22.9% | -123 | |
| EPS (Basic) | 0.00↑100.9% | -0.37↑17.8% | -0.45↑35.7% | -0.70↑54.8% | -1.55 | |
| EPS (Diluted) | 0.00↑100.9% | -0.37↑17.8% | -0.45↑35.7% | -0.70↑54.8% | -1.55 | |
| Weighted Average Shares | 160↑9.3% | 147↑6.6% | 138↑1.5% | 136↑71.6% | 79 | |
| Weighted Average Diluted Shares | 173↑17.7% | 147↑6.6% | 138↑1.5% | 136↑71.6% | 79 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.